Aptamer Group PLC Total Voting Rights (4735O)

TIDMAPTA

RNS Number : 4735O

Aptamer Group PLC

01 February 2023

1 February 2023

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Total Voting Rights

In compliance with the FCA's Disclosure Guidance and Transparency Rules (the "Rules"), the Company announces that, as at the date of this announcement, it has 69,083,594 ordinary shares of GBP0.001 each ("Ordinary Shares") in issue. The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights.

The figure of 69,083,594 Ordinary Shares represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley [phone]

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam Dawes [phone]

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy [phone]

Consilium Strategic Communications

   Matthew Neal / Chris Welsh / Lucy Featherstone                              [phone] 

[e-mail]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer(R) platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBLGDBBSXDGXB

(END) Dow Jones Newswires

February 01, 2023 02:00 ET (07:00 GMT)